Intervention Protocol

You have free access to this content

Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma

  1. Wenbo Shao*,
  2. Jinlong Song

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 23 DEC 2013

DOI: 10.1002/14651858.CD010903

How to Cite

Shao W, Song J. Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD010903. DOI: 10.1002/14651858.CD010903.

Author Information

  1. Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Department of Surgical Oncology (Interventional Therapy), Jinan, Shandong, China

*Wenbo Shao, Department of Surgical Oncology (Interventional Therapy), Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, 440 Jiyan Road,, Jinan, Shandong, 250117, China.

Publication History

  1. Publication Status: New
  2. Published Online: 23 DEC 2013



Additional references

Brok 2008
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
Brok 2009
  • Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment for random error risk in conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38:287-98.
Brown 2007
  • Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. Journal of Vascular and Interventional Radiology 2007;18(12):1469-78. [PUBMED: 18057279]
Bruix 2001
  • Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of Hepatology 2001;35(3):421-30. [PUBMED: 11592607]
Bruix 2005
Bruix 2011
Cabibbo 2010
Camma 2002
  • Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224(1):47-54. [PUBMED: 12091661]
CTU 2012
  • Copenhagen Trial Unit. TSA - Trial Sequential Analysis. (accessed 19 December 2013).
Davila 2004
  • Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127(5):1372-80. [PUBMED: 15521006]
DeMets 1987
DerSimonian 1986
Dodds 1996
  • Dodds HM, Walpole ET, Rivory LP, Strong RW, Pond SM. Disposition of epirubicin after intraarterial administration in lipiodol to patients with hepatocellular carcinoma. Therapeutic Drug Monitoring 1996;18(5):537-43. [PUBMED: 8885116]
Egger 1997
El-Serag 1999
El-Serag 2007
El-Serag 2007a
El-Serag 2012
Forner 2010
Gluud 2013
  • Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 3. Art. No.: LIVER.
Grosso 2008
  • Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovascular and Interventional Radiology 2008;31(6):1141-9. [PUBMED: 18696150]
Higgins 2002
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from
Hong 2006
  • Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clinical Cancer Research 2006;12(8):2563-7. [PUBMED: 16638866]
ICH-GCP 1997
  • International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Pennsylvania, USA: Barnett International/PAREXEL, 1997.
Johnson 1991
  • Johnson PJ, Kalayci C, Dobbs N, Raby N, Metivier EM, Summers L, et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. Journal of Hepatology 1991;13(1):120-7. [PUBMED: 1655867]
Keating 2009
Kim 2009
Kjaergard 2001
  • Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9. [PUBMED: 11730399]
Lai 2005
Lammer 2010
  • Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovascular and Interventional Radiology 2010;33(1):41-52. [PUBMED: 19908093]
Lewandowski 2011
Lewis 2006
  • Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. Journal of Vascular and Interventional Radiology 2006;17(8):1335-43. [PUBMED: 16923981]
Lewis 2009
Llovet 2002
  • Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734-9. [PUBMED: 12049862]
Llovet 2003
Lo 2002
Lundh 2012
Luo 2011
  • Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Annals of Surgical Oncology 2011;18(2):413-20. [PUBMED: 20839057]
Malagari 2008
  • Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovascular and Interventional Radiology 2008;31(2):269-80. [PUBMED: 17999110]
Malagari 2010
  • Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovascular and Interventional Radiology 2010;33(3):541-51. [PUBMED: 19937027]
Marelli 2007
  • Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovascular and Interventional Radiology 2007;30(1):6-25. [PUBMED: 17103105]
McGlynn 2001
Meza-Junco 2012
  • Meza-Junco J, Montano-Loza AJ, Liu DM, Sawyer MB, Bain VG, Ma M, et al. Locoregional radiological treatment for hepatocellular carcinoma: which, when and how?. Cancer Treatment Reviews 2012;38(1):54-62. [PUBMED: 21726960]
Moher 1998
  • Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13. [PUBMED: 9746022]
Nakamura 1989
Oliveri 2011
Poon 2007
  • Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clinical Gastroenterology and Hepatology 2007;5(9):1100-8. [PUBMED: 17627902]
Raoul 1992
RevMan 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Royle 2003
  • Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
Savović 2012
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
Savović 2012a
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [PUBMED: 7823387]
Sottani 2012
  • Sottani C, Poggi G, Quaretti P, Regazzi M, Montagna B, Quaquarini E, et al. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer Research 2012;32(5):1769-74. [PUBMED: 22593459]
Thorlund 2009
  • Thorlund K, Devereaux PJ, Wetterslev J, Gyuatt G, Ioannidis JPA, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. International Journal of Epidemiology 2009;38:276-86.
Thorlund 2010
  • Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
Thorlund 2011
  • Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). 2011 (accessed 19 December 2013): .
van Malenstein 2011
  • van Malenstein H, Maleux G, Vandecaveye V, Heye S, Laleman W, van Pelt J, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011;34(7):368-76. [PUBMED: 21734423]
Varela 2007
  • Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. Journal of Hepatology 2007;46(3):474-81. [PUBMED: 17239480]
Vogl 2011
  • Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR. American Journal of Roentgenology 2011;197(4):W562-W570. [PUBMED: 21940527]
Wetterslev 2008
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
Wetterslev 2009
Wood 2008
  • Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.